MicroRNAs (miRNAs) are involved in tumorigenecity by regulating specific oncogenes and tumor suppressor genes, and their roles in breast cancer stem cells (BCSCs) are becoming apparent. Distinct from the CD44 þ /CD24
Introduction microRNA (miRNA) expression is deregulated in many human cancers (Calin and Croce, 2006; Iorio and Croce, 2009) . In most cases, miRNAs binding to the 3 0 -untranslated regions (3 0 -UTR) of the targeted mRNA leads to degradation or translational repression (Bartel, 2004 ). In some rare cases, miRNA can induce expression of genes with complementary promoter sequences (Place et al., 2008) . Often, one gene can be regulated by multiple miRNAs and one miRNA can repress several target genes. In a broad array of developmental processes, miRNAs fine tune or restrict cellular properties by targeting important transcription factors or key pathways (Stefani and Slack, 2008) ; however, the mechanisms by which miRNAs promote carcinogenesis are not well understood.
In the case of breast cancers, tumor miRNA expressionprofiling studies revealed that specific subgroups of miRNAs were associated with the HER2, ER and PR status (Mattie et al., 2006) . Some miRNAs upregulated in breast cancers have been found to promote tumorigenesis and metastasis. For example, miR-9 was found to target E-cadherin and promote cancer metastasis in most breast cancer cells (Ma et al., 2010) , and miR-103/ 107 was found to target Dicer, and its expression was associated with metastasis and poor prognosis in human breast cancer (Martello et al., 2010) . More recently, miR-21 and miR181b-1 were found to be activated by STAT3 and target PTEN and CYLD tumor suppressors to induce and maintain cellular transformation (Iliopoulos et al., 2010a) . Even in which the mechanism is yet unknown, other studies have shown correlation between miRNA expression and tumor growth, invasion and metastasis (Huang et al., 2008; Tavazoie et al., 2008) . Thus, characterizing the roles of miRNAs in cancer phenotypes is essential in developing a deeper understanding of cancer development, metastasis and invasion.
There are only a few studies reporting the expression of miRNAs in cancer stem cells (CSCs). In the case of breast cancer, various combinations of surface markers have been used to identify and isolate different breast cancer stem cell (BCSC) sub-populations. These include PROCR þ /ESA þ (Hwang-Verslues et al., 2009), CD44 þ / CD24 À/low (Al-Hajj et al., 2003) , ALDH þ (Ginestier et al., 2007) and CD133 þ (Wright et al., 2008) cell populations. In the CD44 þ /CD24 À/low BCSC population, let-7 miRNA, which inhibits self-renewal capacity and promotes differentiation by repressing H-Ras and HMGA2, was found to be downregulated (Yu et al., 2007) . Comparison of miRNA expression profiles between CD44 þ /CD24 À/low BCSCs and non-stem cell populations identified 37 differentially expressed miRNAs (Shimono et al., 2009) . The expression of miR-200s has been shown to downregulate stem cell self-renewal factors, such as BMI1 (Molofsky et al., 2003; Park et al., 2003; Pietersen et al., 2008) , and strongly suppressed the tumor formation ability of BCSCs (Shimono et al., 2009) . miR-200 has also been found to downregulate Suz12, a subunit of a polycomb repressor complex, which has important roles in BCSC formation and maintenance (Iliopoulos et al., 2010b) . However, the importance of other differentially expressed miRNAs in BCSCs remains to be determined.
We recently isolated a novel PROCR þ /ESA þ BCSC sub-population, which is highly tumorigenic and distinct from the CD44 þ /CD24 À/low sub-population (HwangVerslues et al., 2009) . To explore the miRNA regulatory mechanisms in this BCSC sub-population, we performed miRNA expression profiling and found nine upregulated miRNAs in PROCR þ /ESA þ cells, with miR-495 as the most highly upregulated. Expression of miR-495 promoted colony formation, invasion, epithelial-mesenchymal transition (EMT) marker expression and tumorigenicity of breast cancer cells. miR-495 directly downregulated E-cadherin and REDD1, whereas miR-495 itself was upregulated by E12/E47 transcription factors. These results define a regulatory pathway centered on miR-495 that functions upstream of the established REDD1-mTOR pathway to confer hypoxia tolerance. Thus, elevated expression of miR-495 is likely to be one factor that defines the highly tumorigenic PROCR þ /ESA þ sub-population as well as other CSC sub-populations.
Results miR-495 is upregulated in two different breast cancer stem cell sub-populations We profiled miRNA expression in a newly identified BCSC sub-population (PROCR þ /ESA þ ) and in corresponding non-CSCs (PROCR
from the MDA-MB-231 cell line using a quantitative real-time PCR-based expression array (Table 1) . Nine miRNAs were found to be upregulated in the PROCR þ / ESA þ BCSC sub-population, with miR-495 being the most highly upregulated. Comparing this profile with the miRNA expression profile, derived from CD44 þ / CD24 À/low BCSC population, (Shimono et al., 2009) found that miR-495 was upregulated more than by 30-fold (DC t X5) relative to the non-CSC population in both types of BCSCs (Table 1) . Consistent with this, miR-495 was upregulated in CD44 þ /CD24 À/low BCSCs from a luminal breast cancer cell line SKBR3 (Supplementary Figure S1A ). However, the remaining eight miRNAs upregulated in PROCR þ /ESA þ cells were unique. Thus, it is possible that miR-495 upregulation may be a mechanism shared at least by these two different BCSC populations.
miR-495 expression promotes colony formation and tumorigenecity of breast cancer cells To test whether miR-495 was important in maintaining stem cell characteristics, we overexpressed miR-495 in the non-CSC sub-population (PROCR À /ESA À ) of MDA-MB-231 cells, and performed soft-agar colony formation assay to quantify tumorigenic ability (Hwang-Verslues et al., 2009) . miR-495 overexpression increased colony-forming ability of the non-CSC population by almost three-fold (Figure 1a) , whereas the growth rates of the miR-Ctrl and miR-495-overexpressing cells were similar (Supplementary Figure S2) . When miR-495 was inactivated by anti-miR-495 morphilino oligo (si-miR-495), the colony-forming ability of the PROCR þ /ESA þ BCSC sub-population was decreased significantly (Figure 1b) . Furthermore, overexpression of miR-495 enhanced the colony-forming ability of the bulk population of MDA-MB-468 (Figure 1c ), MDA-MB-361 ( Figure 1d ) and SKBR3 cells (Supplementary Figure S3 ). These three cell lines contain their own distinct stem cell sub-populations (Yu et al., 2007; Hwang-Verslues et al., 2009) , thus, miR-495 could promote colony formation at least in three different cellular contexts. However, overexpression of miR-495 alone was not able to induce normal epithelial cells to Figure S5 ) and the expression of miR-495 remained higher in the miR-495 tumors at the end of the assay (Figure 1g ). These results indicated that miR-495 promotes tumorigenic activity. )-overexpressing miR-Ctrl or miR-495 were injected into the fourth mammary fat pads of a non-obese diabetic/severe combined immunodeficientmouse. Data from three mice are presented. Nonlinear regression (curve fit) analysis was used to test for significant differences between the tumor growth curves derived from miR-Ctrl and miR-495-expressing cells for each mouse (P-value is indicated). Picture of one representative mouse is shown in Supplementary Figure S5 Figure S6A ). As epithelial tumor cells need to acquire EMT to allow invasion, the expression of key EMT markers E-cadherin, vimentin and N-cadherin was examined. In miR-495-overexpressing MDA-MB-231 cells, E-cadherin was downregulated, whereas vimentin and N-cadherin were upregulated ( Figure 1i ). miR-495 also promoted EMT marker expression, especially N-cadherin and vimentin, in SKBR3 cells (Supplementary Figure S6B) . A similar pattern of EMT marker expression was also observed in tumors derived from miR-495-overexpressing cells (Figure 1j ). Protein levels of E-cadherin were also decreased by about 40% in miR-495-overexpressing MDA-MB-231 cells ( Figure 1k ). As MDA-MB-231 cells express relatively low levels of E-cadherin, MCF-7 cells were used to further demonstrate miR-495 downregulation of E-cadherin ( Figure 1l ). Similar to MDA-MB-231 cells, a 40% decrease was observed in miR-495-overexpressing MCF-7 cells. These results indicated that E-cadherin, a key EMT marker, could be one of the target genes of miR-495.
miR-495 downregulates E-cadherin expression
To identify miR-495 targets, important for maintaining the CSC phenotype and promoting tumorigenesis, we identified genes differentially expressed in the PROCR þ /ESA þ and PROCR À /ESA À sub-populations by cDNA microarray analysis (Supplementary Table  S1 ), and used the TargetScan algorithm (Lewis et al., 2005) to identify putative miR-495 target genes. Merger of these two data sets found 19 genes that were both differentially expressed between PROCR þ /ESA þ and PROCR À /ESA À sub-populations and also contained miR-495 target sequences in their 3 0 -UTRs ( Figure 2a ). Among these 19 genes, E-cadherin was identified, as it was downregulated significantly in the BCSC subpopulation and contained a miR-495 target sequence in its 3 0 -UTR. Immunoblotting using PROCR þ /ESA þ and PROCR À /ESA À MDA-MB-231 cells confirmed the downregulation of E-cadherin. Consistent with the gene-expression profiling, E-cadherin protein level was decreased 40% in the BCSC sub-population ( Figure 2b ). Downregulation of E-cadherin was also observed in CD44 þ /CD24 À/low BCSCs from SKBR3 cells (Supplementary Figure S1B ).
To directly demonstrate that miR-495 targets E-cadherin, the 3 0 -UTR of E-cadherin was cloned into a pGL3-basic luciferase reporter plasmid for transient reporter assays (Figure 2c ). miR-495 expression did not affect luciferase expression of the basal plasmid, without miR-495 target sites added (Figure 2d ), verifying that this system was suitable to study miR-495 function. The construct, containing the E-cadherin 3 0 UTR, with one miR-495 target sequence, was suppressed by 30% by miR-495 expression ( Figure 2e ). Mutation of the miR-495 target sequence in the E-cadherin 3 0 -UTR restored expression to the control level ( Figure 2f) . Together, these results demonstrated that the target sequence in the 3 0 -UTR of E-cadherin was sufficient for miR-495 regulation and could contribute to the negative expression correlation between endogenous miR-495 and E-cadherin.
miR-495 downregulates REDD1 expression to promote hypoxia resistance Tumor cells need to acquire ability to bypass or adapt to hypoxia stress for progression. As miR-495-overexpressing (Figure 1f ), it is possible that miR-495 targets important factors in hypoxia signaling to release the cells from hypoxia stress. Among the 19 miR-495 target genes, REDD1 was downregulated in the BCSC sub-population, and contained multiple miR-495 target sequences in its 3 0 -UTR (Figure 2a ). REDD1 represses cell growth in hypoxia by inhibiting mTOR signaling (Brugarolas et al., 2004; DeYoung et al., 2008) . Consistent with the gene expression profiling, REDD1 protein levels were decreased 50% in the BCSC sub-population (Figure 3a) , and its expression levels were also downregulated in the BCSCs from SKBR3 cells (Supplementary Figure S1C) . To further verify whether REDD1 was miR-495 target, we ectopically expressed miR-495 or scrambled miRNA control (miR-Ctrl) in bulk MDA-MB-231 cells. Upon miR-495 overexpression, the REDD1 mRNA expression decreased significantly (Figure 3b ). We also examined the protein levels of REDD1 and found that REDD1 was decreased about 40% in miR-495-overexpressing MDA-MB-231 cells (Figure 3c ).
To directly demonstrate that miR-495 could suppress REDD1, four potential miR-495 target sequences identified in the REDD1 3 0 -UTR were cloned into two pGL3-basic luciferase reporter plasmids (REDD1-1 and REDD1-2) (Figure 3d ). In response to miR-495 overexpression, luciferase acitivity, derived from the REDD1-1 reporter construct, which contained the first three target sequences, was reduced by half ( Figure 3e) . When all the three target sequences were mutated (REDD1-1.3m), the luciferase activity was fully restored (Figure 3f ), thus demonstrating that miR-495 specifically targets these sequences. Reporter assays, using single-and double-mutated target sequences, showed that the second and the third target sequences were critical for REDD1 downregulation by miR-495 (Supplementary Figure S7) , whereas the fourth target sequence was only slightly repressed by miR-495 expression (Figure 3g ). Together, these results demonstrated that target sequences in the 3 0 -UTR of REDD1 were sufficient for miR-495 to downregulate REDD1 expression. It has been well established that upregulation of REDD1 in hypoxia can stabilize tuberous sclerosis complex (TSC2/1), which sequentially inhibits Rheb to block mTOR signaling, and leads to cell growth arrest (Inoki et al., 2003; Brugarolas et al., 2004; Reiling and Hafen, 2004; DeYoung et al., 2008) . As miR-495 suppressed REDD1 expression, we tested whether miR-495-expressing cells were more tolerant to hypoxia by examining REDD1 protein levels, and ribosomal S6 kinase (S6K) phosphorylation in miR-Ctrl and miR-495-overexpressing cells over a hypoxia time course (Figure 4a ). Loss of S6K phosphorylation during hypoxia serves as an indicator of inhibited mTOR signaling (Mamane et al., 2006) . REDD1 steadily increased in miR-Ctrl-overexpressing cells upon hypoxia, but was impaired in miR-495-overexpressing cells (Figure 4b ). miR-Ctrl-expressing cells had decreased S6K T389 phosphorylation ( Figures  4a and c) , consistent with REDD1 inhibition of mTOR signaling. In contrast, S6K T389 phosphorylation remained unchanged in miR-495-overexpressing cells (Figure 4c ). This suggested that miR-495 expression hinders the REDD1 blockage of mTOR signaling, possibly leading to hypoxia resistance.
To directly determine whether miR-495-expressing cells were better able to proliferate in hypoxia, a 5-day hypoxia cell growth assay was performed (Figure 4d ). miR-495-expressing cells proliferated faster than miRCtrl-expressing cells throughout the hypoxia time course. Similar results were also observed using immortalized normal mammary epithelial H184B5F5/M10 (M10) cells-expressing miR-495 and miR-Ctrl (Supplementary Figure S8 ). To further demonstrate that promotion of cell proliferation in hypoxia by miR-495 was mainly via inhibition of REDD1 induction, another hypoxia cell growth assay was performed using miR-495-expressing MDA-MB-231 cells, which also ectopically expressed REDD1 (Figure 4e ). These cells proliferated as slowly as the miR-Ctrl cells throughout the hypoxia time course. The results suggested that inhibition of REDD1 induction was a key mechanism by which miR-495 promoted cell proliferation in hypoxia. These findings indicated one of the mechanisms by which miR-495-expressing cells can generate larger tumors in mice (Figure 1f) . Interestingly, the proliferation of miR-Ctrl-expressing MDA-MB-231 cells was restrained in the first 24 h of hypoxia, and then gradually recovered (Figures 4d and e) . Similarly, the proportion of BCSCs and expression of miR-495 increased at 24 h after hypoxia treatment (Figures 4f  and g ), consistent with previous studies, which showed enrichment of the CSC sub-population during early stages of hypoxia (Keith and Simon, 2007; Heddleston et al., 2010) . Interestingly, the expression of miR-495 was continuously elevated through the 5-day time course, whereas the proportion of BCSCs was elevated through 48 h and then decreased after 72 h in hypoxia (Figures 4h  and i) . These results implied that even though the prevalence of BCSCs decreased through asymmetric division, miR-495 expression remained high in the progeny cells to promote proliferation under hypoxia.
Upregulation of miR-495 by transcription factor E12/E47
These data raised the question of what upstream factor could be responsible for upregulation of miR-495 in BCSC sub-populations. By using the UCSC table browser (Karolchik et al., 2004 ) and the TRANSFAC 6.0 database (http://www.biobase-international.com/index. php?id=transfac) we identified an E47/basic helix-loophelix-binding site at À226 to À241 of the miR-495 promoter region (Figure 5a ). E12 and E47, also known as TCF3, are alternative spliced products of the E2A gene. E2A is the founding member of the vertebrate class I basic helix-loop-helix gene family (Murre et al., 1989) , and is known to bind E-Boxes (CANNTG) of its target promoters. Further examination found three E-Boxes at À325 to À330, À678 to À683 and À820 to À825 of the miR-495 promoter region ( Figure 5a ). As transcription factors E12 and E47 have been shown to regulate the cell cycle progression of hematopoietic stem cells and have an important role in stem cell pool maintenance (Semerad et al., 2009) , we investigated whether E12/E47 could activate the miR-495 promoter.
Expression of E12 or E47 in MDA-MB-231 cells increased miR-495 expression by nearly two-fold (Figure 5b ). To directly determine the transactivation ability of E12 and E47, the miR-495 proximal promoter (À900 bp) was cloned into the pGL3.basic luciferase reporter vector and transfected in MDA-MB-231 cells overexpressing E12 or E47. This transient reporter assay showed a significant increase in miR-495 promoter activity in both E12 and E47-expressing cells (Figure 5c ).
Chromatin immunoprecipitation assay found binding of both E12 and E47 to the E47 site of the miR-495 promoter (Figures 5d and e) . A strong binding of E-Box EB3 (CATTTG) by E12 was also observed (Figure 5d ). (Figure 5f ). Next, we examined the effect of E12/E47 expression on REDD1 and E-cadherin expression and found reductions of 80% in E12-overexpressing cells and 60% in E47-overexpressing cells (Figure 5g ). This was a stronger repression than that observed with miR-495 overexpression alone (Figures 1i, 3b) . Thus, in addition to increasing miR-495 expression that represses REDD1 and Ecadherin, E12/E47 could regulate REDD1 and E-cadherin expression through other mechanisms.
Discussion

E12 and E47 activate the expression of miR-495
The present results demonstrated a regulatory pathway, whereby transcription factors E12 and E47 upregulate miR-495, which then contributes to maintaining CSC BCSC sub-populations (Shimono et al., 2009) . Assays using multiple cell lines, which express different stem cell markers, (Hwang-Verslues et al., 2009) indicated that, regardless of cellular context, miR-495 could maintain or promote colony-forming ability, promote EMT marker expression and downregulate E-cadherin and REDD1 (Figures 1-4) . These observations further suggested that although heterogeneous BCSCs might have dissimilar ability in tumorigenicity, migration and invasion, and may develop into different types of breast cancers; there might be shared regulatory pathways that maintain CSC phenotypes.
miR-495 targeted genes have roles in hypoxia resistance and maintaining/promoting cancer stem cell properties The targets of miR-495 are genes likely to be important in many types of CSCs. In MDA-MB-231 cells, miR-495 upregulation hindered REDD1 induction and allowed cells to proliferate continuously in a hypoxic environment (Figure 4 ). Short-term (48 h) culture in hypoxia has been shown to expand the sub-population of cells expressing CSC marker CD133 (Soeda et al., 2009) , and to enhance the stem-like phenotypes (McCord et al., 2009) . Although most studies have focused on the roles of hypoxia-inducible factors in inducing CSC phenotypes and conferring tumorigenic potential (Covello et al., 2006; Heddleston et al., 2009) , our data, in contrast, demonstrate the role of miR-495 promoting cell proliferation in hypoxia. These findings suggest an alternative pathway leading to hypoxia resistance and ultimately determining tumorigenic potential in CSCs.
It is likely that at least some of the other potential miR-495 target genes, identified in our analysis, (Figure 2a ) also contribute to the function of miR-495 in promoting CSC properties. Some of these potential miR-495 targets, such as the forkhead box O transcription factor 1 and circadian clock gene Per2, are known to have tumor suppressor functions. Downregulated forkhead box O transcription factor 1 expression has been observed in several cancers including breast tumors, and overexpression of forkhead box O transcription factor 1 in breast cancer cells led to decreased cell number through both inhibition of cell cycle and increased cell death (Guttilla and White, 2009 ). Likewise, downregulation of Per2 has also been observed in breast cancers (Winter et al., 2007) and overexpression of Per2 inhibited tumor growth, whereas Per2 suppression increased cancer cell proliferation and tumorigenesis (Yang et al., 2009) . Therefore, miR-495 suppression of forkhead box O transcription factor 1 and Per2 could also promote the oncogenic state of BCSCs. Some of the 17 remaining genes on the list of potential miR-495 Figure 2a ), might be important in contributing to the tumorigenic phenotype of this sort of BCSC population.
Overexpression of additional miRNAs may partly contribute to specific breast cancer stem cell properties In addition to miR-495 and its target genes, other miRNAs identified in this study might be more unique to PROCR þ /ESA þ cells, and important to the tumorigenic phenotype and CSC properties of these cells. For instance, miR-195, which is upregulated in PROCR þ / ESA þ BCSCs (Table 1) , has been reported to regulate tumor suppressor Wee1 to promote cell cycle G2/M transition in human embryonic stem cells (Qi et al., 2009) . Interestingly, there are several E-boxes in the 1-kb miR-195 promoter region (Supplementary Table S2 Overall, the data presented here defined a regulatory pathway centered on miR-495 in BCSCs (Figure 6 ). Specific underlying BCSC populations are thought to contribute partly to the different types of breast cancers and diversified clinical outcomes. miR-495 is now known to be upregulated in at least two of these BCSC populations. Determining whether miR-495 is upregulated in additional types of BCSCs, as well as whether the upstream regulation of miR-495 by E12/E47, and downstream target genes are conserved across different cell types, will allow the generality of this miR-495-centered regulatory pathway to be established and miR-495 promotes tumorigenecity WW Hwang-Verslues et al potentially to be used as a therapeutic target to specifically target BCSCs.
Materials and methods
Cell culture
Human breast cancer cell lines MDA-MB-231, MDA-MB-468, MDA-MB-361 and HEK-293T cells were cultured in Dulbecco's modied Eagle's medium supplemented with 10% fetal bovine serum and 1 Â antibiotics/antimycotics. H184B5F5/M10 cells were cultured in Dulbecco's modied Eagle's medium/F12 supplemented with 5% horse serum, 20 ng/ml epidermal growth factor, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 mg/ml insulin and 1 Â antibiotics/ antimycotics in a humidified 37 1C incubator supplemented with 5% CO 2 .
Plasmids and reagents REDD1 and E-cadherin 3 0 -UTRs were amplified from MDA-MB-231 genomic DNA and cloned into pGL3-promoter vectors between luciferase sequence and poly A signal, using restriction enzyme XbaI. Mutagenesis of the miR-495 target sequences in REDD1 and E-cadherin 3 0 -UTRs were performed using site-directed mutagenesis (Agilent Technologies, Inc., Cedar Creek, TX, USA) following the instructions from the manufacturer. The REDD1 cDNA was amplified from human Mammalian Gene Collection-verified full-length cDNA (NIH.MGC.46) and cloned into a pLVX-IRES-Neo bicistronic lentiviral expression vector (Clontech, Mountain View, CA, USA) using EcoRI and XbaI. E12/E47 expression plasmids pHBAneo #56 were generously provided by Dr Cornelis Murre (University of California, San Diego, CA, USA) (Gunning et al., 1987) . E12 and E47 cDNA were cloned into a pLKO AS2.hyg bi-cistronic lentiviral expression vector using NheI and AscI. The miR-495 proximal promoter was amplified from WI38 genomic DNA, and cloned into a pGL3basic reporter plasmid using XhoI and MluI. All cloned and mutated genes were verified by sequencing. Primers used for cloning were listed in Supplementary Table S3. miR-495 and control siRNA pRNA-CMV3.1/Neo-expressing vectors were purchased from GenScript (Piscataway, NJ, USA). LentimiR-Ctrl and lenti-miR-495 lentiviral stocks were purchased from BiOSETTIA (San Diego, CA, USA). miR-495 and miR-Ctrl morpholino oligos were purchased from Gene Tools, LLC (Philomath, OR, USA). The morpholino oligos were delivered to cells using Endo-porter following the manufacturer's instruction.
RNA isolation, reverse-transcription and miRNA expression quantification Total RNA from cell culture was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and reverse-transcribed with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) for gene expression analysis or with Taqman miRNA Reverse Transcription kit (Applied Biosystems) for miRNA quantification according to instructions from the manufacturers.
Real-time PCR assay
Quantitative real-time RT-PCR was performed using Fast SYBR-Green master mix for gene expression and Taqman microRNA Assays for miRNA expression according to the manufacturer's instruction and analyzed on a StepOnePlus Real-Time PCR system (Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogenase mRNA and U6B RNA were used as an internal control for mRNA and miRNA expression, respectively. Expression levels were calculated according to the relative DC t method. All primers were listed in Supplementary  Table S4. miRNA expression profiling miRNA expression of BCSC and non-CSC sub-populations was profiled using PCR-based TaqMan Human MicroRNA Array A (Applied Biosystems). In brief, 900 ng of total RNA from each sub-population was reverse-transcribed and the miRNAs were quantified with the TaqMan MicroRNA Reverse Transcription kit and MegaplexTM Pools for Micro-RNA Expression Assays from Applied Biosystems. Reactions were performed on an Applied Biosystems 7900HT Fast RealTime PCR system. Soft-agar colony formation assay Soft-agar colony formation assay was performed as previously described (Hwang-Verslues et al., 2009) . In brief, 2500 cells were seeded in a layer of 0.35% agar Dulbecco's modied Eagle's medium/fetal bovine serum over a layer of 0.5% agar/ Dulbecco's modied Eagle's medium/fetal bovine serum in a well of a 12-well plate. Additional complete media was added every 3-5 days to supply growth supplements. On day 14, after seeding, crystal violet-stained colonies were counted.
Invasion assay
Cells (10 4 ) were seeded in the top chamber with Matrigelcoated membrane (24-well BD Falcon HTS Fluoro Block insert; pore size, 8 mm; BD Biosciences, Bedford, MA, USA) in growth medium without serum. Medium supplemented with serum was used as a chemoattractant in the lower chamber. After 24 h incubation, the invaded cells were fixed with methanol, stained with 4 0 ,6-diamidino-2-phenylindole and counted with fluorescence microscopy.
Immunoblotting
Immunoblot analysis was performed after 8% SDS-PAGE, with overnight incubation of a 1:3000 dilution of anti-REDD1 Figure 6 Model of miR495 function as a central signaling element in breast cancer stem cells. In BCSCs, miR-495 is upregulated by transcription factor E12/E47. The upregulated miR-495 maintains CSC phenotypes, and promotes EMT and cancer cell invasion by suppression of E-cadherin expression. miR-495 also targets REDD1 to inhibit its induction upon hypoxia, which leads to constitutive hypoxia resistant cell proliferation. Transient reporter assay Cells of 80% confluence were transfected using Lipofectamine 2000 (Invitrogen). For miR-495 promoter reporter assay, luciferase reporter gene construct (1 mg) and 10 ng of the pGL4-74 Renilla luciferase construct (for normalization) were co-transfected per well of a 12-well plate. For REDD1 and E-cadherin 3 0 -UTR reporter assays, 200 ng of the miRNA expression vector, 20 ng of the 3 0 -UTR reporter gene construct and 20 ng of the pGL4-74 Renilla luciferase construct were co-transfected per well of a 96-well plate. Cell extracts were prepared at 26-48 h after transfection, and the luciferase activity was measured using the Dual-Glo Luciferase Assay System (Promega, Madison, WI, USA).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was performed as previously reported (Hwang-Verslues and Sladek, 2008) . Immunoprecipitations were performed with anti-E12 (V-18, Santa Cruz, Santa Cruz, CA, USA), anti-E47 (N-649, Santa Cruz) and corresponding control (immunoglobulin G) antibodies. Quantitative real-time RT-PCR was performed as described above.
Cell growth assay
To determine growth curves, 10 4 or 5000 cells were seeded in each well of a 6-or 12-well plate, respectively. At 24 h after seeding, cells were incubated in hypoxia chamber INVIVO 400 (Ruskinn, Bridgend, UK) with 0.5-1% oxygen concentration. Cell numbers were counted every day until day 5. Two-way analysis of variance was used to test for significant differences between miR-Ctrl and miR-495-overexpressing cells or between cells expressing miR-495 alone and miR-495 and REDD1 co-overexpressing cells.
Cell labeling and flow cytometry
Cell labeling and sorting were performed as previously described (Hwang-Verslues et al., 2009) . Antibodies used for cell labeling were rat-anti(a)-human(h)PROCR-PE (BD Bioscience), mouse-a-hESA-647 (eBioscience, San Diego, CA, USA), m-a-hCD44-APC and m-a-hCD24-PE (using antibody titration suggested by the supplier). Isotype controls were used for each cell labeling experiment. Live cell sorting was done using a BD FACS Aria with 100 mm nozzle following the manufacturer instructions.
Mouse tumorigenicity assay
Animal care and experiments were approved by the Institutional Animal Care and Utilization Committee of Academia Sinica (IACUC#080085). Non-obese diabetic/severe combined immunodeficient fat pads were injected with 4 Â 10 5 cancer cells mixed with Matrigel (BD bioscience) (1:1). Tumor volumes were evaluated every 7 days after initial detection. Nonlinear regression (curve fit) analysis was used to test for significant differences between tumor growth curves, derived from miR-Ctrl and miR-495 expressing cells, for each mouse using GraphPad Prism version 5.01 (GraphPad Software, Inc., La Jolla, CA, USA).
Statistical analysis
Except of the quantification for specific immunoblots, mouse tumorigenesis assay and cell growth assay, all data are presented as means ± s.d., and Student's t-test was used to compare control and treatment groups. Asterisk (*) indicates statistic significance with P-value o0.05.
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